The researchers cautioned the "safety of semaglutide use is poorly documented" during the postpartum period, when women go through physiological and hormonal changes
[PMID: 40355389] PubMed record related to this compound for laboratory literature review
This medication has also been approved for treating serious liver disease, known as MASH, in adults with moderate-to-advanced fibrosis
Both supply chains start at the same place For sema, tirz, and most GLP-1 family peptides, the bulk active pharmaceutical ingredient (API) comes overwhelmingly from a small set of large Chinese peptide synthesis houses
doi: 10.1056/NEJMoa1612917 61 BarrittASTMarshmanENoureddinM
Semaglutide has randomized trial evidence in nonalcoholic steatohepatitis demonstrating improvement in key disease activity outcomes. Tirzepatide also has randomized trial evidence in metabolic dysfunctionassociated steatohepatitis (MASH) with liver fibrosis, supporting improvements in steatohepatitis-related endpoints. Clinical takeaway: GLP-1 and GLP-1/GIP therapies can reduce liver fat and liver injury activity in metabolic liver disease settings., 3) They Improve Cardiometabolic Risk Factors That Overlap With Vascular Inflammation Vascular inflammation is an umbrella term
